Filing Details
- Accession Number:
- 0001415889-23-008647
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-05-23 17:50:11
- Reporting Period:
- 2023-05-22
- Accepted Time:
- 2023-05-23 17:50:11
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1285819 | Omeros Corp | OMER | Pharmaceutical Preparations (2834) | 911663741 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1472158 | J. Thomas Cable | C/O Omeros Corporation 201 Elliott Avenue West Seattle WA 98119 | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2023-05-22 | 5,000 | $5.30 | 40,067 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2023-05-22 | 5,000 | $6.53 | 35,067 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2023-05-22 | 5,000 | $0.00 | 5,000 | $5.30 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2014-05-22 | 2023-05-23 | No | 4 | M | Direct |
Footnotes
- This transaction was executed in multiple trades at prices ranging from $6.49 to $6.59. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which the transactions referenced in this footnote were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.
Billionaire Hedge Funds
